Physician profile
Daniel Edwin Benyo
NPI 1023438777
$9,967.27
in general payments reported to CMS, 2019-2025
46 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $1,379 · 2021: $2,328 · 2022: $2,187 · 2023: $2,570 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,703.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,369.29 | 2019-2023 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,026.75 | 2019-2023 | |
| Lilly USA, LLC | $897.31 | 2019-2023 | Mounjaro, Amyvid, Trulicity |
| Astrazeneca Pharmaceuticals LP | $536.91 | 2019-2023 | Breztri |
| Abbvie INC. | $515.23 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.03 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $375.49 | 2020-2023 | Arexvy, Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $239.52 | 2021-2023 | |
| Mylan Specialty L.P. | $216.03 | 2021-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $175.37 | 2020-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $170.14 | 2022-2023 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $165.93 | 2019-2022 | |
| Biogen, INC. | $161.98 | 2020-2022 | |
| Amarin Pharma, INC. | $159.56 | 2020-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Benyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.